title: IL-17 Blockade in Psoriasis: Friend or Foe in Cardiovascular Risk?
abstract: Psoriasis is a chronic, immune-mediated inflammatory disorder associated with systemic inflammation and a significantly increased risk of cardiovascular disease. Common pathologic mechanisms are likely involved in the pathogenesis of psoriasis and atherosclerosis, including similar inflammatory cytokine profiles and proinflammatory cell types. The hypothesis that aggressive treatment of skin inflammation may decrease the risk of developing atherosclerosis and consequently cardiovascular disease is currently a focus of major attention. Interleukin (IL)-17 may be an important cytokine linking skin disease to vascular disease/inflammation. However, the role of IL-17 in atherosclerosis is still controversial, as IL-17 may exhibit pro-atherogenic or anti-atherogenic effects depending on the specific tissue, cellular, and immune context. Given the development of several IL-17 inhibitors, the investigation of IL-17 inhibition impact on cardiovascular outcome is extremely important.
authors.affiliation: Department of Dermatology, Centro Hospitalar do Porto, Porto, Portugal. torres.tiago@outlook.com.|Instituto de Ciências Biomédicas Abel Salazar, University of Portugal, Porto, Portugal. torres.tiago@outlook.com.
authors.forename: Tiago
authors.initials: T
authors.lastname: Torres
authors.affiliation: Department of Dermatology, Centro Hospitalar do Porto, Porto, Portugal.
authors.forename: Inês
authors.initials: I
authors.lastname: Raposo
authors.affiliation: Department of Dermatology, Centro Hospitalar do Porto, Porto, Portugal.|Instituto de Ciências Biomédicas Abel Salazar, University of Portugal, Porto, Portugal.
authors.forename: Manuela
authors.initials: M
authors.lastname: Selores
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D050197:Atherosclerosis / Q000453:epidemiology* / Q000276:immunology; D003879:Dermatologic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000276:immunology; D020381:Interleukin-17 / Q000037:antagonists & inhibitors* / Q000097:blood / Q000276:immunology*; D053760:Interleukin-23 Subunit p19 / Q000037:antagonists & inhibitors / Q000276:immunology; D008297:Male; D009928:Organ Specificity; D011565:Psoriasis / Q000188:drug therapy* / Q000276:immunology; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D058504:Th17 Cells / Q000276:immunology / Q000378:metabolism; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; C508717:IL17A protein, human; C508840:IL23A protein, human; D020381:Interleukin-17; D053760:Interleukin-23 Subunit p19; C439524:TNF protein, human; D014409:Tumor Necrosis Factor-alpha